Joint Venture Growth Slate Run is forming a joint venture with Arna Pharma to create a scaled-up U.S. specialty pharmaceutical platform, signaling a clear path to co-develop and manufacture higher value products at scale. This presents sales opportunities to propose supply arrangements, contract manufacturing, and private-label partnerships with specialty pharma companies seeking reliable US capacity and streamlined regulatory pathways.

Portfolio Expansion With a portfolio of over 30 product families and a disciplined approach to portfolio development, there is a strong opportunity to upsell and cross-sell to wholesalers, distributors, pharmacies, and healthcare providers. A business development plan can target channel partners looking to broaden their generics offerings with a compliant, reliable supplier backed by established manufacturing partnerships and a robust regulatory track record.

Regulatory Reliability Leadership brings extensive experience across commercial operations, regulatory affairs, quality, and supply chain, underscoring a proven ability to obtain FDA approvals and maintain regulatory compliance. This reliability is a key differentiator for risk-averse buyers such as hospitals and large distributors seeking steady supply continuity for their generic portfolios.

Channel Expansion Slate Run serves a broad U.S. customer base that includes wholesalers, distributors, pharmacies, and healthcare providers, creating a foundation to expand distribution and private-label opportunities. Leveraging this reach, you can propose expanded product territories, faster time-to-market for new generics, and co-branded initiatives with strategic channel partners.

Launch Expertise Past success launching cinacalcet hydrochloride tablets and ongoing platform development demonstrate the team's capability to develop and bring to market complex generics. This track record can attract specialty clinics, nephrology-focused distributors, and hospital systems seeking reliable entrants in higher-need therapeutic areas and partnerships that accelerate market access.